Arvinas Review (January 2026)
Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.
Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.
What is Arvinas's Revenue?
Arvinas's estimated revenue is $23M.
What does Arvinas do?
Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.
How fast is Arvinas growing?
Arvinas has grown by 24.1% in the last 3 months according to SimilarWeb.
How do people find Arvinas?
39% of visitors come directly to Arvinas. 47% find them through search engines. 6% discover them through social media.
How do people interact with Arvinas?
Last month, Arvinas received 14.1K visitors who spent an average of 00:29 minutes on the website and visited 1.6 different pages per session. Overall, 42% of people bounce on the first visit.
Who uses Arvinas?
Arvinas's top market is US and they receive 68% of visitors from there. The 2nd is IN with 14%. The 3rd is GB with 7%.
Traffic Growth (last 3 months)
Traffic Sources
Top Countries
Technology detection powered by advanced web analysis
Powered byTechlist.aiValeritas
Discover V-Go, a lightweight, wearable insulin delivery device designed to simplify basal-bolus therapy for adults with diabetes.More
Connectiverx
ConnectiveRx supports patients, keeps medication affordable and creates programs that make it easier to stay on medication, all from one source. More
Celularity
Diaceutics
Diaceutics have worked on every Precision Medicine brought to market in partnership with leading pharmaceuticals. #bettertestingbettertreatment.More
Kallyope
At Kallyope, we are leveraging insights into neural signaling pathways and developing innovative medicines for the treatment of migraine and metabolic disorders.More